Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions.
A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers ... with asthma and COPD under a 510 ...
The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...
Hosted on MSN2d
Medical Report: Are asthma inhalers bad for the environment?Certain medications commonly used to treat asthma and COPD can damage the environment and worsen respiratory issues. KYW ...
Asthma Quality of Life Questionnaire; AUC: Area under the curve; COPD: Chronic obstructive pulmonary disease; FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity; ICS: Inhaled ...
OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...
In Chicago public schools that adopted a stock inhaler program, more students who used a stock inhaler for asthma symptoms ...
An asthma attack can come on suddenly or as a gradual worsening of symptoms. Here are the key signs you may be experiencing ...
A program that supplies schools with stock inhalers was well received by school health personnel/nurses in Illinois, according to two posters presented here.Both posters were presented at the 2025 ...
1d
ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback